Tumor volumes in T3 supraglottic cancers treated with radiotherapy in the modern era: A study of the Canadian Head & Neck Collaborative Research Initiative.
T3 supraglottic cancer
head and neck cancer
laryngeal cancer
radiotherapy
tumor volume
Journal
Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541
Informations de publication
Date de publication:
20 Dec 2023
20 Dec 2023
Historique:
revised:
02
10
2023
received:
04
07
2023
accepted:
07
12
2023
medline:
20
12
2023
pubmed:
20
12
2023
entrez:
20
12
2023
Statut:
aheadofprint
Résumé
To evaluate the association of primary tumor volume (TV) with overall survival (OS) and disease-free survival (DFS) in T3 N0-3M0 supraglottic cancers treated with intensity-modulated radiotherapy (IMRT). This was a retrospective cohort study involving 239 patients diagnosed with T3 N0-3M0 supraglottic cancers between 2002 and 2018 from seven regional cancer centers in Canada. Clinical data were obtained from the patient records. Supraglottic TV was measured by neuroradiologists on diagnostic imaging. Kaplan-Meier method was used for survival probabilities, and a restricted cubic spline Cox proportional hazards regression analysis was used to analyze TV associations with OS and DFS. Mean (SD) of participants was 65.2 (9.4) years; 176 (73.6%) participants were male. 90 (38%) were N0, and 151 (64%) received concurrent systemic therapy. Mean TV (SD) was 11.37 (12.11) cm Increasing primary tumor volume is associated with worse OS and DFS in T3 supraglottic cancers treated with IMRT, with no clear threshold. The findings suggest that patients with larger tumors and poor baseline laryngeal function may benefit from upfront laryngectomy with adjuvant radiotherapy.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.
Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991;324:1685-1690.
Forastiere AA, Zhang Q, Weber RS, et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol. 2013;31:845-852.
Hoffman HT, Porter K, Karnell LH, et al. Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. Laryngoscope. 2006;116:1-13.
Wolf GT. Reexamining the treatment of advanced laryngeal cancer: the VA laryngeal cancer study revisited. Head Neck. 2010;32(1):7-14.
Olsen KD. Reexamining the treatment of advanced laryngeal cancer. Head Neck. 2010;32(1):1-7.
Divakar P, Davies L. Trends in incidence and mortality of larynx cancer in the US. JAMA Otolaryngol Head Neck Surg. 2022;149:34-41. doi:10.1001/jamaoto.2022.3636
Daly ME, Le QT, Jain AK, et al. Intensity-modulated radiotherapy for locally advanced cancers of the larynx and hypopharynx. Head Neck. 2011;33(1):103-111.
Wolf GT, Bellile E, Eisbruch A, et al. Survival rates using individualized bioselection treatment methods in patients with advanced laryngeal cancer. JAMA Otolaryngol Head Neck Surg. 2017;143(4):355-366.
Grover S, Swisher-McClure S, Mitra N, et al. Total laryngectomy versus larynx preservation for T4a larynx cancer: patterns of care and survival outcomes. Int J Radiat Oncol Biol Phys. 2015;92(3):594-601.
Steuer CE, El-Deiry M, Parks JR, Higgins KA, Saba NF. An update on larynx cancer. CA Cancer J Clin. 2017;67:31-50.
Eskander A, Blakaj DM, Dziegielewski PT. Decision making in advanced larynx cancer: an evidenced based review. Oral Oncol. 2018;86:195-199.
Forastiere AA, Ismaila N, Lewin JS, et al. Use of larynx-preservation strategies in the treatment of laryngeal cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2018;36:1143-1169.
Tamaki A, Miles BA, Lango M, Kowalski L, Zender CA. AHNS series: do you know your guidelines? Review of current knowledge on laryngeal cancer. Head Neck. 2018;40(1):170-181.
Nurkic S, Nurkic T, Morris CG, Amdur RJ, Mendenhall WM. Preradiotherapy tumor volume in local control of squamous cell carcinoma of the supraglottic larynx. Am J Clin Oncol. 2018;41:1089-1093.
Dziegielewski PT, Reschly WJ, Morris CG, et al. Tumor volume as a predictor of survival in T3 glottic carcinoma: a novel approach to patient selection. Oral Oncol. 2018;79:47-54. doi:10.1016/j.oraloncology.2018.02.015
Rutkowski T. The role of tumor volume in radiotherapy of patients with head and neck cancer. Radiat Oncol. 2014;9:23.
Malik NH, Fu R, Hainc N, et al. Association of primary tumor volume with survival in patients with T3 glottic cancer treated with radiotherapy: a study of the Canadian head & neck collaborative research initiative. JAMA Otolaryngol Head Neck Surg. 2022;149:103-109. doi:10.1001/jamaoto.2022.3996
Widel M. Implementing Laboratory Toxicity Grading for CTCAE Version 5.
Murohashi K, Hara Y, Saigusa Y, et al. Clinical significance of Charlson comorbidity index as a prognostic parameter for patients with acute or subacute idiopathic interstitial pneumonias and acute exacerbation of collagen vascular diseases-related interstitial pneumonia. J Thorac Dis. 2019;11:2448-2457.
Harrell FE. General aspects of fitting regression models. In: Harrell EF Jr, ed. Regression Modeling Strategies: With Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis. Springer International Publishing; 2015:13-44.
Lee EW, Wei LJ, Amato DA, Leurgans S. Cox-type regression analysis for large numbers of small groups of correlated failure time observations. In: Klein JP, Goel PK, eds. Survival Analysis: State of the Art. Springer Netherlands; 1992:237-247.
Austin PC, Lee DS, Fine JP. Introduction to the analysis of survival data in the presence of competing risks. Circulation. 2016;133:601-609.
Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496-509.
Zhou B, Fine J, Latouche A, Labopin M. Competing risks regression for clustered data. Biostatistics. 2012;13:371-383.
Hair JF Jr, Black WC, Babin BJ, Anderson RE. Multivariate Data Analysis (7th ed.). Pearson. 2009.
R Core Team. R: A Language and Environment for Statistical Computing. 2013.
Li MM, Zhao S, Eskander A, et al. Stage migration and survival trends in laryngeal cancer. Ann Surg Oncol. 2021;28(12):7300-7309.
Raitiola H, Pukander J, Laippala P. Glottic and supraglottic laryngeal carcinoma: differences in epidemiology, clinical characteristics and prognosis. Acta Otolaryngol. 1999;119(7):847-851.
Kourelis K, Papadas T, Vandoros G, Goumas P, Sotiropoulou-Bonikou G. Glottic versus supraglottic tumors: differential molecular profile. Eur Arch Otorhinolaryngol. 2008;265:79-84.
Wachters JE, Kop E, Slagter-Menkema L, et al. Distinct biomarker profiles and clinical characteristics in T1-T2 glottic and supraglottic carcinomas. Laryngoscope. 2020;130(12):2825-2832.
Hoebers F, Rios E, Troost E, et al. Definitive radiation therapy for treatment of laryngeal carcinoma. Strahlenther Onkol. 2013;189:834-841.
Nguyen TK, Nguyen EK, Warner A, Louie AV, Palma DA. Failed randomized clinical trials in radiation oncology: what can we learn? Int J Radiat Oncol Biol Phys. 2018;101(5):1018-1024.
Cosetti M, Yu GP, Schantz SP. Five-year survival rates and time trends of laryngeal cancer in the US population. Arch Otolaryngol Head Neck Surg. 2008;134(4):370-379.
Overgaard J, Hansen HS, Specht L, et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6&7 randomised controlled trial. Lancet. 2003;362(9388):933-940.